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Summary The metastatic non-small cell lung cancer (NSCLC) still remains an untreatable disease, and the
role played by chemotherapy has yet to be defined. The new immunotherapeutic strategies, such as interferon
and IL-2, seem to be also less effective, since they generally determine only a stabilisation of disease. On the
basis of previous experimental results suggesting a synergistic action between IL-2 and the pineal neurohor-
mone melatonin (MLT), a study was started to evaluate the clinical efficacy and toxicity of a neuroimmuno-
therapeutic combination consisting of IL-2 plus MLT as a first line therapy in metastatic NSCLC. The study
included 20 patients (adenocarcinoma: 10; epidermoid cell carcinoma: 7; large, cell carcinoma: 3). MLT was
given orally at a dose of 10mg day-' at 8.00 pm every day, starting 7 days before the onset of IL-2
administration. IL-2 was given subcutaneously at a dose of 3 x 106 IU m-2 every 12 h for 5 days/week for 4
weeks, corresponding to one cycle of immunotherapy. In responder patients or in those with stable disease, a
second cycle was given after a rest-period of 21 days. A partial response was achieved in 4/20 (20%) patients.
Ten other patients had a stable disease (50%), whereas the last six patients progressed. Toxicity was low in all
cases.
This study shows that the neuroimmunotherapeutic therapy with IL-2 and the pineal hormone MLT may
represent a new effective and well tolerated treatment in metastatic NSCLC, with results comparable to those
obtained with chemotherapy, but with an apparent lower biological toxicity.
In the last 50 years, no medical therapy has substantially
improved the prognosis of non-small cell lung cancer
(NSCLC) (Hansen, 1987). The prognosis of metastatic
NSCLC still remains poor, with median survival generally
not greater than 20 weeks. Chemotherapy has a limited
impact, and does not determine any evident benefit on the
survival time. Therefore, these poor results justify the inves-
tigation of new medical strategies in the treatment of metas-
tatic NSCLC, such as immunotherapy and hormonotherapy.
Because of its fundamental role in the activation of an
effective host antitumour immune response, interleukin-2 (IL-
2) represents one of the most promising cytokines in the
immune control of cancer growth (Grimm et al., 1982). At
present, very few results are available about the activity of
IL-2 in NSCLC (Rosenberg et al., 1987; Ardizzoni et al.,
1990; Krigel et al., 1991). Preliminary data would suggest
that IL-2, despite its biological efficacy in stimulating the
immune system, has only a little activity, when it is given
alone, in the treatment of advanced NSCLC. As far as the
endocrine therapy is concerned, the hormonal approach in
the treatment of NSCLC may be considered as a new inter-
esting strategy on the basis of recent evidences, suggesting
that lung cancer growth is stimulated by somatomedin-C
(Minuto et al., 1988), also termed insulin-like growth factor-I
(IGF-I). At present, two different pharmacological approaches
are available to reduce the endogenous IGF-I production,
represented by somatostatin long-acting agonists (Lamberts,
1987), and by the pineal hormone melatonin (MLT) (Smythe
et al., 1974). MLT has also appeared to exert a direct cyto-
static action on some human cancer cell lines (Hill & Blask,
1988) and to induce tumour regressions in humans (Lissoni
et al., 1989). Moreover, MLT circadian secretion has been
shown to play a fundamental role in maintaining an optimal
immune performance (Maestroni et al., 1986). Within its
immunomodulating properties, MLT has been proven to
antagonise the immunosuppression induced by adrenal
steroids or chemotherapeutic agents (Maestroni et al., 1986)
and to enhance the antitumour efficacy of IL-2 in some
experimental conditions (Maestroni et al., 1990). Preliminary
clinical studies would suggest that MLT may induce a stabi-
lisation of disease in a reasonable number of mestastatic
NSCLC patients progressed under chemotherapy (Lissoni et
al., 1989), and to reduce some side-effects related to IL-2
immunotherapy of cancer (Lissoni et al., 1990).
On the basis of the potential importance of the pineal
indole in the endocrine and immune control of lung cancer
growth, we have designed an experimental neuroimmuno-
therapeutic regimen with IL-2 and MLT in the treatment of
advanced NSCLC patients.
Materials and methods
The study included 20 consecutive metastatic NSCLC
patients (M/F:14/6; median age 55 years, range 38-70), who
were admitted to the Hospital of Monza to receive IL-2 plus
MLT as a first line therapy of the metastatic disease. Eleven
patients had been previously treated with surgery, while the
other nine patients showed a metastatic disease at the time of
the diagnosis of lung cancer. Eligibility criteria included:
histologically proven NSCLC, metastatic disease, measure-
able lesions, no previous chemotherapy, age less than 70
years, and an expected survival greater than 3 months.
Patients with second neoplasms, brain metastases or impor-
tant cardiorespiratory diseases were not included in the
study. The experimental protocol was explained to each
patient, and informed consent was obtained. Histotype was
adenocarcinoma in ten, epidermoid cell carcinoma in seven,
and large cell carcinoma in the remaining three patients.
Moreover, all patients had visceral lesions as dominant meta-
stasis sites (lung: 11; lung plus liver, eight; liver: one).
MLT was supplied by Helsinn Chemicals SA (Breganzona-
Switzerland). Human recombinant IL-2 was supplied by
Euro-Cetus (Amsterdam-Holland). MLT was given orally at
a dose of 10 mg/daily at 8.00 pm, without interruption, start-
ing 7 days before the onset of IL-2 injection. We decided to
give MLT during the evening on the basis of experimental
data, suggesting that the biological activity of the pineal
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hormone is greater when it is administered during the dark
period of the day (Bartsch & Bartsch, 1981). Moreover, a
pretreatment with MLT was proposed on the basis of our
previous experimental data, which showed that the maximum
synergistic action may be achieved when MLT is given before
the onset of IL-2 administration (Maestroni et al., 1990).
IL-2 was injected subcutaneously into different parts of the
abdominal wall at a dose of 9 million IUm2 twice daily
(8.00 am and 8.00 pm) for 2 days as an induction phase,
followed by 3 million IU m-2 twice daily for 5 days/week for
4 consecutive weeks, corresponding to one cycle of therapy.
In responder patients or in those with a stabilisation of
disease, a second cycle was given after a rest period of 21
days, during which the only MLT was administered.
Radiological examinations were repeated after each cycle
of therapy, then every 2 months. Liver metastases were inves-
tigated by CT scan. Routine laboratory tests and electrocar-
diogram were repeated weekly during IL-2 injection. Clinical
response and toxicity were evaluated according to WHO
criteria. Complete response (CR) was a complete resolution
of all clinically evaluable disease for at least one month;
partial response (PR) was defined as at least 50% reduction
in the sum of the products of the longest perpendicular
diameters ofmeasurable lesions for at least one month; stable
disease (s.d.) was defined as no objective tumour regression
or increase greater than 25%; progressive disease (PD) was
defined as at least 25% increase in measurable lesions or the
appearance of new lesions. Patients were considered as evalu-
able when they received at least one cycle of therapy.
For immune detections, venous blood samples were collect-
ed during the morning before the onset of IL-2 adminstra-
tion, and at 1-week intervals until the end of the cycle. In
each sample, we have measured the number of lymphocytes,
T lymphocytes (CD3), NK cells (CD16) and IL-2 receptor
expressing lymphocytes (CD25). Lymphocyte subsets were
measured with a flow cytometric analysis by FACS and
monoclonal antibodies supplied by Becton-Dickinson (Milan-
Italy). On the same samples, serum levels of neopterin were
also measured as a marker of macrophage activation.
Finally, serum levels of tumour necrosis factor (TNF) and
soluble IL-2 receptor (SIL-2R) were measured. Neopterin
concentrations were measured with the double antibody RIA
method (Henning, Berlin-Germany). TNF values were detect-
ed by the IRMA method (Medgenix Diagnostics, Bruxelles-
Belgium). SIL-2R levels were measured by an enzyme
immunoassay (T Cell Sciences, Cambridge, MA).
Data were statistically analysed by the Student's t test,
chi-square test, and analysis of variance according to New-
man Keuls test adjusted for a correction factor.
Results
All patients were fully evaluable. Clinical data and response
to therapy are reported in Table I. No patient achieved a CR
during the treatment. A PR was obtained in 4/20 (20%)
patients. The response was seen after the first cycle of
immunotherapy in one patient and after two cycles in the
other three cases. Among responder patients, two were
affected by lung adenocarcinoma, and the other two by
epidermoid cell carcinoma. No significant difference in res-
ponse rate was seen between epidermoid cell carcinoma and
adenocarcinoma patients (2/7 vs 2/10). On the contrary, no
tumour regression was seen in the three patients with large
cell carcinoma. Ten patients (50%) achieved a s.d., with a
median duration of 3.5+ months (range 2-7 months), with-
out any significant relation to the histotype (adenocarcinoma:
6/10; epidermoid cell carcinoma: 4/7). The remaining 6/20
(30%) patients progressed after the first cycle of immuno-
therapy. The median overall survival time was 5+ months
(2-14+).
Toxicity was accepted in all patients, and in particular no
cardiovascular complication occurred during IL-2 administ-
ration. Fever higher than 38°C was seen in 11/20 patients,
but it was generally limited to the first two days of IL-2
induction. The other toxicities were, as follows: vomiting
grade 1-2: 3/20; anorexia 6/20; pruritus 3/20; depression:
2/20; nodules in the injection site: 7/20; hyperglycemia: 1/20.
No patient had anaemia during IL-2 plus MLT therapy.
Moreover, no patient showed a fall in platelet number; on
the contrary, thrombocytosis higher than 1 million mm-3
occurred in one of the four responder patients. Platelet mean
number progressively increased during the administration of
IL-2 plus MLT, without, however, any significant difference
between peak values and those seen before therapy
(410,000 ± 60,000 vs 290,000 ± 40,000 mm-3; x- ± s.e.).
The mean number of lymphocytes, T lymphocytes, NK
cells and CD25-positive cells, as well as that of eosinophils,
significantly increased during the administration of IL-2 plus
MLT, as shown in Figure 1. Eosinophilia greater than 20%
occurred in 16/20 patients. Mean serum levels of neopterin
and TNF significantly increased during IL-2 plus MLT
Table I Clinical data and response to therapy in 20 advanced non-small cell lung cancer patients treated with IL-2 plus
melatonin
Response
Clinical Response duration Progression Survival
Cases Sex Age Histotypesa Sites ofdisease responseb sites (months) sites (months)
I F 60 A Lung, adrenal PD - Adrenal 14+
2 M 63 A Lung, liver SD 3 Lung 5
3 M 55 E Lung, nodes SD 2 Lung 7
4 F 39 A Lung PR Lung 12 Lung 13+
5 M 57 A Lung, liver SD 7 Liver 10
6 M 56 A Lung, bone PR Lung 4 Lung 6
7 F 57 E Lung, liver SD - 6 Liver, bone 11
8 F 61 E Lung, bone, skin PD - - Lung, bone 3
9 M 49 LC Lung, liver PD - - Lung, pleura 2
10 M 38 A Lung, liver, bone SD - 5 Skin 9
11 M 41 A Lung, liver, pericardium SD - 2 Liver 5
12 M 40 LC Lung, liver PD - - Lung 3
13 F 42 A Lung, liver, bone SD - 3 Bone 5
14 M 70 E Liver SD - 5+ - 5+
15 M 56 E Lung SD - 4+ - 4+
16 M 68 E Lung PR Lung 3+ - 3
17 F 55 A Lung PD Lung 3
18 M 62 LC Lung, nodes PD - - Brain 3
19 M 70 E Lung PR Lung 3+ -
20 M 64 A Lung SD 3+ - 3
aA: adenocarcinoma; E: epidermoid cell carcinoma; LC: large cell carcinoma. bPR: partial response; SD; stable disease;
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Figure 1 Changes in lymphocyte, T lymphocyte (CD3), NK cell
(CD16), CD25-positive cell and eosinophil number (mean±s.e.)
during the neuroimmunotherapy with IL-2 and MLT in 20 meta-
static non-small cell lung cancer patients. *P<0.05 vs before;
**P<0.01 vs before; ***P<0.001 vs before. @ Lymphocytes; 0
Eosinophils; 0 T lymphocytes (CD3); 0 NK cells (CD16);0
CD25 + lymphocytes.
therapy, with a peak on the first-second week of treatment
(see Figure 2). Finally, SIL-2R mean concentrations observed
during therapy were significantly higher than those seen
before, as illustrated in Figure 3.
Discussion
This phase II study shows that the neuroimmunotherapeutic
association between IL-2 and the pineal hormone MLT is
able to induce objective tumour regressions in patients with
advanced NSCLC, with clinical results comparable to those
reported with chemotherapy (Hansen, 1987). However, it has
to be considered that the tumour regression obtained with an
immunotherapeutic strategy depends on an activation of host
immune antitumour response, whereas that achieved with
chemotherapy is associated with a suppression of host
immune defenses, induced by the antiblastic drugs them-
selves. The chemotherapy-induced damage of the immuno
system would negatively influence the prognosis of cancer
patients, and could explain the low survival time described in
the literature in advanced NSCLC patients treated with
chemotherapy, including the responders ones. The suppres-
sion of host defenses does not occur during the immune-
therapy, which, in contrast, stimulates the generation of an
effective anticancer reaction, with a potential benefit on the
survival time. In fact, in agreement with the results pre-
viously reported in the literature with higher doses of IL-2
alone given intravenously (Ardizzoni et al., 1990; Krigel et
al., 1991), this study seems to suggest that IL-2 immuno-
therapy may determine a long survival time in advanced
NSCLC patients, including those with liver metastases.
Objective tumour regression rate obtained in advanced
NSCLC with IL-2 plus MLT seems to be clearly higher than
that reported in literature with IL-2 alone, whose efficacy has
appeared to be ranging between 0% (Ardizzoni et al., 1990)
and 4% (Krigel et al., 1991). The mechanisms responsible for
the low responsivity of NSCLC to IL-2 immunotherapy in
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Figure 2 Changes in serum levels of neopterin and TNF
(mean ±s.e.) during the neuroimmunotherapy with IL-2 and
MLT in 20 metastatic non-small cell lung cancer patients.
*P<0.05 vs before; **P<0.01 vs before; ***P<0.001 vs before.
* Neopterin; 0 TNF.
Figure 3 Changes in SIL-2R
the neuroimmunotherapy with
non-small cell lung cancer
**P<0.01 vs before.
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respect to other tumour histotypes, such as renal cancer and
malignant melanoma (Rosenberg et al., 1987), have still to be
explained. However, they might depend at least in part on
the documented inhibitory role of bronchoalveolar macro-
phages on NK cells and on other immune cells involved in
the anticancer response (Bordignon et al., 1982). The appar-
ent enhancement of the clinical efficacy of IL-2 in NSCLC
induced by the concomitant administration of the pineal
hormone MLT might be due to a modulation of macro-
phage-mediated suppressive events which occur during IL-2
immunotherapy concomitantly to the activation of an
effective immune response (Lissoni et al., 1991). This hypo-
thesis is supported by the lower increase of the macrophage
marker neopterin and of SIL-2R during IL-2 plus MLT in
respect to the values previously observed by ourselves with
IL-2 alone (Lissoni et al., 1991). On the contrary, the macro-
phage secretion of TNF, which is important in mediating
tumour regression, does not seem to be negatively influenced
by the concomitant administration of MLT. In our previous
clinical studies with MLT alone in advanced NSCLC patients
(Lissoni et al., 1989), we observed an improvement in the
survival time only in patients with lung, bone and soft tissue
lesions as dominant metastasis sites, whereas no benefit was
seen in the present of liver metastases; this study would
suggest that the association between MLT and IL-2 may
prolong the survival time also in patients with liver involve-
ment.
As far as the immunobiological effects are concerned, the
increase in lymphocyte, T lymphocyte, NK cell and CD25-
positive cell mean number obtained with IL-2 plus MLT
seems to be comparable with that reported by other authors
with IL-2 alone (Atzpodien et al., 1990); the only increase in
eosinophil number seems to be more pronounced with IL-2
plus MLT than that obtained with IL-2 alone, by suggesting
a possible synergistic action between MLT and cytokines
involved in the stimulation of eosinophil production, such as
interleukin-3 and interleukin-5.
In conclusion, this study shows that the neuroimmuno-
therapeutic regimen consisting of IL-2 plus MLT is an
effective and well tolerated therapy in metastatic NSCLC,
with results comparable to those obtained with chemo-
therapy, by representing a new possible therapeutic strategy
in the treatment of disseminated lung cancer. Randomised
studies with IL-2 vs IL-2 plus MLT will be needed to estab-
lish the impact of the pineal hormone MLT on the efficacy of
IL-2 in NSCLC.
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